List of articles with "Rigel Pharmaceuticals"

Rigel at Healthcare Conf.

Rigel at Healthcare Conf.

United States South San Francisco Health Innovations Rigel Pharmaceuticals Nasdaq RIGL
Five-Year Findings on REZLIDHIA

Five-Year Findings on REZLIDHIA

United States South San Francisco Rigel Pharmaceuticals REZLIDHIA mIDH1 AML
Rigel at Jefferies

Rigel at Jefferies

United States Cancer Research South San Francisco Rigel Pharmaceuticals Hematologic Disorders
Rigel Q3 2025 Update

Rigel Q3 2025 Update

United States South San Francisco Rigel Pharmaceuticals R289 TAVALISSE
Rigel ASH Presentations 2025

Rigel ASH Presentations 2025

United States South San Francisco Rigel Pharmaceuticals R289 mIDH1 AML
R289 Study Enrollment

R289 Study Enrollment

United States South San Francisco Rigel Pharmaceuticals R289 MDS
Rigel Inducement Grants

Rigel Inducement Grants

USA stock options South San Francisco Rigel Pharmaceuticals restricted stock
Rigel's Q2 2025 Results

Rigel's Q2 2025 Results

United States South San Francisco Rigel Pharmaceuticals TAVALISSE GAVRETO
Rigel Grants Announced

Rigel Grants Announced

USA NASDAQ South San Francisco Rigel Pharmaceuticals Inducement Grants
Rigel at Jefferies Conference

Rigel at Jefferies Conference

United States New York biotechnology Rigel Pharmaceuticals Jefferies Conference
Rigel's Presentations at Conferences

Rigel's Presentations at Conferences

United States South San Francisco Rigel Pharmaceuticals REZLIDHIA GAVRETO
Rigel's Q1 Performance

Rigel's Q1 Performance

USA South San Francisco Rigel Pharmaceuticals R289 TAVALISSE
Rigel Inducement Grants

Rigel Inducement Grants

United States stock options South San Francisco Rigel Pharmaceuticals Inducement Grants
Rigel Settles TAVALISSE Patent Case

Rigel Settles TAVALISSE Patent Case

United States South San Francisco Rigel Pharmaceuticals TAVALISSE Annora Pharma
Dr. Frohlich Joins Rigel

Dr. Frohlich Joins Rigel

USA oncology South San Francisco Rigel Pharmaceuticals Mark Frohlich
Rigel's 2024 Financial Success

Rigel's 2024 Financial Success

USA South San Francisco Rigel Pharmaceuticals TAVALISSE REZLIDHIA
Fostamatinib Trials

Fostamatinib Trials

None Bethesda Rigel Pharmaceuticals sickle cell disease Fostamatinib
Rigel Pharmaceuticals Update

Rigel Pharmaceuticals Update

USA South San Francisco Rigel Pharmaceuticals TAVALISSE REZLIDHIA
Rigel's R289 Receives FDA Designation

Rigel's R289 Receives FDA Designation

United States South San Francisco Rigel Pharmaceuticals R289 MDS
Rigel at J.P. Morgan

Rigel at J.P. Morgan

United States San Francisco Cancer Treatments Healthcare Conference Rigel Pharmaceuticals
Rigel Grants Stock Options

Rigel Grants Stock Options

United States stock options South San Francisco Rigel Pharmaceuticals RIGL
R289 Phase 1b Study Results

R289 Phase 1b Study Results

United States San Diego Rigel Pharmaceuticals R289 ASH 2024
FDA Fast Track for R289

FDA Fast Track for R289

United States South San Francisco Rigel Pharmaceuticals R289 MDS

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.